Geron Corporation (GERN) Stock Analysis
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $1.11, but acceptable to hold if already in. Reasons: DATA_ISSUE: analyst_target_implausible (raw $3.40 vs price $1.10 — ratio 3.1×). Rejected, falling back to technical TP.; Market cap $0.72B below $1B minimum.
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk... Read more
Hold if already holding. Not a fresh buy at $1.11, but acceptable to hold if already in. Reasons: DATA_ISSUE: analyst_target_implausible (raw $3.40 vs price $1.10 — ratio 3.1×). Rejected, falling back to technical TP.; Market cap $0.72B below $1B minimum. Chart setup: No clear chart pattern; technical signals are mixed. Market cap $0.72B below $1B minimum. Not in investable universe. Score 6.1/10, moderate confidence.
Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 56d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent developments
updated 2026-06-10Recent Developments — Geron Corporation
Latest news
- NEWS Geron To Present Real-World Moffitt Cancer Center Study Showing RYTELO (imetelstat) Safety And Efficacy In Lower-Risk MD — benzinga May 12, 2026
- NEWS Earnings Scheduled For May 6, 2026 — benzinga May 6, 2026
- NEWS Geron Reports Q1 2026 Results: Full Earnings Call Transcript — benzinga May 6, 2026 neutral
- NEWS Geron Expects FY26 RYTELO Net Product Revenue $220M-$240M; Sees Total Operating Expenses $230M-$240M — benzinga May 6, 2026 neutral
- NEWS Geron Q1 EPS $(0.01) Beats $(0.02) Estimate, Sales $51.771M Beat $50.582M Estimate — benzinga May 6, 2026 positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $1.11, but acceptable to hold if already in. Reasons: DATA_ISSUE: analyst_target_implausible (raw $3.40 vs price $1.10 — ratio 3.1×). Rejected, falling back to technical TP.; Market cap $0.72B below $1B minimum. Chart setup: No clear chart pattern; technical signals are mixed. Market cap $0.72B below $1B minimum. Not in investable universe. Target $1.42 (+27.9%), stop $1.06 (−4.7%), A.R:R 0.0:1. Score 6.1/10, moderate confidence.
Take-profit target: $1.42 (+29.1% upside). Target $1.42 (+27.9%), stop $1.06 (−4.7%), A.R:R 0.0:1. Stop-loss: $1.06.
DATA_ISSUE: analyst_target_implausible (raw $3.40 vs price $1.10 — ratio 3.1×). Rejected, falling back to technical TP.; Market cap $0.72B below $1B minimum.
Geron Corporation trades at a P/E of N/A (forward 17.2). TrendMatrix value score: 8.3/10. Verdict: Hold.
12 analysts cover GERN with a consensus score of 4.0/5. Average price target: $3.
What does Geron Corporation do?Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products...
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.